Provided by Tiger Trade Technology Pte. Ltd.

Imunon, Inc.

1.64
+0.06003.80%
Post-market: 1.650.0052+0.32%19:59 EDT
Volume:58.85K
Turnover:95.07K
Market Cap:9.20M
PE:-0.46
High:1.67
Open:1.61
Low:1.59
Close:1.58
52wk High:6.96
52wk Low:1.47
Shares:5.61M
Float Shares:5.32M
Volume Ratio:0.68
T/O Rate:1.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5719
EPS(LYR):-6.8265
ROE:-429.72%
ROA:-77.99%
PB:4.75
PE(LYR):-0.24

Loading ...

Imunon General Counsel Susan Eylward Disposes of 2,449 Common Shares Worth $3,992.54

Reuters
·
Aug 18

Imunon: Buy Rating Reiterated as Phase 3 IMNN-001 Progress and Extended Cash Runway Support Unchanged $10 Price Target

TIPRANKS
·
Aug 13

Imunon Menawarkan Opsi Gaji Berbasis Saham Bagi Eksekutif Hingga 100% Dari Gaji Pokok, Dengan Tambahan Saham Insentif

Reuters
·
Aug 12

Sellas Life Sciences Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 12

Imunon Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 11

Imunon Q2 EPS USD -0.54

Reuters
·
Aug 11

Imunon Q2 Net Loss Widens Slightly as R&D Costs Rise

Reuters
·
Aug 11

Imunon Q2 EPS $(0.54) Beats $(0.93) Estimate

Benzinga Earnings
·
Aug 11

Imunon Reports Second Quarter 2026 Financial Results and Provides Business Update

THOMSON REUTERS
·
Aug 11

Imunon Q2 Net Income USD -2.8 Million

THOMSON REUTERS
·
Aug 11

IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewswire
·
Aug 11

Top News Today/Canada: Barrick Settles Newmont Dispute, Clearing Way to List Its Gold Assets

Dow Jones
·
Aug 11

Imunon Inc Expected to Post a Loss of 93 Cents a Share - Earnings Preview

Reuters
·
Aug 08

Imunon Schedules Q2 Results, Business Update Conference Call

Reuters
·
Aug 04

Imunon Inc Expected to Post a Loss of 93 Cents a Share - Earnings Preview

Reuters
·
Jul 31

Imunon Says Phase 3 Ovation 3 Ovarian Cancer Trial Enrollment Outpaces Plan

Reuters
·
Jul 30

Imunon - Imnn-001 Demonstrates Favorable Safety Profile with no Serious Immune-Related Adverse Events

THOMSON REUTERS
·
Jul 30

Imunon - Reports Enrollment Rate Exceeding Forecast in Ovation 3 Trial

THOMSON REUTERS
·
Jul 30

Imunon Reports Strong Enrollment Momentum in Phase 3 Ovation 3 Trial of Imnn-001 in Advanced Ovarian Cancer

THOMSON REUTERS
·
Jul 30

Imunon - Projects Enrollment Completion in Q2 2029 for Ovation 3 Trial

THOMSON REUTERS
·
Jul 30